New Delhi, April 4 – India’s drug regulators are increasing their oversight of rapidly growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.This move comes as the...
New Delhi, March 12 Aurobindo Pharma announced on Thursday that it has received an inspection report from the US health regulator, classifying its wholly-owned subsidiary's manufacturing unit in Andhra Pradesh as having a "Voluntary Action Indicated" (VAI) classification, which indicates...
New Delhi, February 14 Piramal Pharma has stated that the US health regulator has issued a Form 483 with four observations after inspecting its manufacturing plant based in Telangana.The US Food and Drug Administration (USFDA) conducted an inspection of the company's plant in Digwal...
compliance
digwal
drug maker
food, drug and cosmetic (fd&c) act
form 483
inspection
manufacturing plant
pharmaceuticalinspection
piramal pharma
regulatory filing
telangana
us food and drug administration (usfda)
usfda inspection
voluntary action indicated (vai)